Search Results - "KOBAYASHI, Yoshimitsu"

Siliceous Sandstones Used in Local Khmer Temples in Battambang, Ta Keo, and Kampong Cham Provinces, Cambodia by Uchida, Etsuo, Kobayashi, Yoshimitsu

“…Siliceous sandstones used in Khmer temples such as the Prasat Basset, Wat Ek Phnom, and Phnom Banan temples in Battambang Province, Phnom Chisor and Ta Prohm…”
Get full text

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer by Takahashi, Shin, Sakamoto, Yasuhiro, Denda, Tadamichi, Takashima, Atsuo, Komatsu, Yoshito, Nakamura, Masato, Ohori, Hisatsugu, Yamaguchi, Tatsuro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Amagai, Kenji, Kondo, Hitoshi, Shimada, Ken, Sato, Atsushi, Yuki, Satoshi, Okita, Akira, Ouchi, Kota, Komine, Keigo, Watanabe, Mika, Morita, Satoshi, Ishioka, Chikashi

“…Oxaliplatin (OX) and irinotecan (IRI) are used as key drugs for the first‐line treatment of metastatic colorectal cancer (mCRC). However, no biomarkers have…”
Get full text

Early gastric mixed neuroendocrine‐non‐neuroendocrine neoplasm with early poor prognosis after endoscopic submucosal dissection: A case report by Tomita, Yusuke, Seki, Hideyuki, Matsuzono, Emi, Kobayashi, Yoshimitsu, Sogabe, Susumu, Sugai, Nozomu, Fujita, Jun, Suzuki, Akira

“…Early gastric mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs) are rare diseases, with no data on their incidence and prognosis. We report the case…”
Get full text

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101) by Harada, Kazuaki, Yamamura, Takahiro, Muto, Osamu, Nakamura, Michio, Sogabe, Susumu, Sawada, Kentaro, Nakano, Shintaro, Yagisawa, Masataka, Muranaka, Tetsuhito, Dazai, Masayoshi, Tateyama, Miki, Kobayashi, Yoshimitsu, Kato, Sosuke, Hatanaka, Kazuteru, Kawamoto, Yasuyuki, Yuki, Satoshi, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

“…The effects of gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin…”
Get full text

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer by Kawamoto, Yasuyuki, Komatsu, Yoshito, Yuki, Satoshi, Sawada, Kentaro, Muranaka, Tetsuhito, Harada, Kazuaki, Nakatsumi, Hiroshi, Fukushima, Hiraku, Ishiguro, Atsushi, Dazai, Masayoshi, Hatanaka, Kazuteru, Nakamura, Michio, Iwanaga, Ichiro, Uebayashi, Minoru, Sogabe, Susumu, Kobayashi, Yoshimitsu, Miyagishima, Takuto, Ono, Kota, Sakamoto, Naoya, Sakata, Yuh

“…In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen…”
Get full text

Adaptive Speed Control of Wheeled Mobile Robot on Uncertain Road Condition by Terada, Kyosuke, Miura, Hiroyasu, Okugawa, Masayuki, Kobayashi, Yoshimitsu

“…[abstFig src='/00280005/10.jpg' width='300' text='Adaptive speed control for mobile robot' ] This study investigated the effectiveness of a simple adaptive…”
Get full text

Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report by Yoshikawa, Ayumu, Terashita, Katsumi, Morikawa, Kenichi, Matsuda, Soichiro, Yamamura, Takahiro, Sarashina, Koichiro, Nakano, Shintaro, Kobayashi, Yoshimitsu, Sogabe, Susumu, Takahashi, Kazuhiro, Haba, Shin, Oda, Hisashi, Takahashi, Tatsuro, Miyagishima, Takuto, Sakamoto, Naoya

“…Hepatitis C virus (HCV) infection remains the main cause of liver disease and can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV may…”
Get full text

Colorectal cancer chemotherapy and QOL (benefits and problems of outpatient-chemotherapy) by Nakatsumi, Hiroshi, Yuki, Satoshi, Kobayashi, Yoshimitsu, Komatsu, Yoshito

Get more information

HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment by Harada, Kazuaki, Nakano, Shintaro, Kawamoto, Yasuyuki, Sawada, Kentaro, Miyagishima, Takuto, Sogabe, Susumu, Kobayashi, Yoshimitsu, Ito, Ken, Sato, Atsushi, Yu, Chen, Dazai, Masayoshi, Yuki, Satoshi, Yokota, Isao, Komatsu, Yoshito

“…647 Background: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) showed improved survival compared to…”
Get full text

A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan by Sogabe, Susumu, Yuki, Satoshi, Takano, Hironobu, Kobayashi, Yoshimitsu, Nakatsumi, Hiroshi, Sasaki, Takahide, Kawamoto, Yasuyuki, Fukushima, Hiraku, Iwanaga, Ichiro, Uehata, Yasuko, Komatsu, Yoshito, Asaka, Masahiro

“…A40 -year-old woman visited our hospital with adenocaricinoma of the sigmoid colon with multiple liver metastases and ovarian metastasis. Because of a stenosis…”
Get more information

High-density pulse width modulation recording and rewritable capability in GeSbTe phase-change system using visible laser beam at low linear velocity by UCHINO, K.-I, TAKADA, K.-I, OHNO, T, YOSHIDA, H, KOBAYASHI, Y

“…Write and erase characteristics at low linear velocity in GeSbTe phase-change optical disks have been studied using 488 nm and 680 nm visible lasers. Good…”
Get full text

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors by Hofheinz, Ralf‐Dieter, Deplanque, Gaël, Komatsu, Yoshito, Kobayashi, Yoshimitsu, Ocvirk, Janja, Racca, Patrizia, Guenther, Silke, Zhang, Jun, Lacouture, Mario E., Jatoi, Aminah

“…Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that extends patient survival across a variety of tumor types. EGFR…”
Get full text

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403) by Kawamoto, Yasuyuki, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Hayashi, Hideyuki, Yuki, Satoshi, Sawada, Kentaro, Yagisawa, Masataka, Nakano, Shintaro, Sakamoto, Naoya, Komatsu, Yoshito

“…Lessons Learned Because S‐1 is orally administered, OX‐IRIS does not necessitate the continuous infusion of 5‐FU and is more convenient. The recommended dose…”
Get full text

A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy by Kawamoto, Yasuyuki, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Hayashi, Hideyuki, Yuki, Satoshi, Sawada, Kentaro, Yagisawa, Masataka, Nakano, Shintaro, Sakamoto, Naoya, Komatsu, Yoshito

“…Background. OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be…”
Get full text

MO2-2 HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma by Dazai, Masayoshi, Harada, Kazuaki, Yamamura, Takahiro, Muto, Osamu, Nakamura, Michio, Sogabe, Susumu, Sawada, Kentaro, Yagisawa, Masataka, Muranaka, Tetsuhito, Nakano, Shintaro, Tateyama, Miki, Ito, Ken, Saito, Rika, Kobayashi, Yoshimitsu, Kato, Sosuke, Miyagishima, Takuto, Kawamoto, Yasuyuki, Yuki, Satoshi, Sakata, Yuh, Komatsu, Yoshito

Get full text

Repetition of Helicobacter cinaedi infections during chemotherapy for malignant lymphoma by Ono, Masayoshi, Ohnishi, Shunsuke, Onishi, Reizo, Takahashi, Shojiro, Kobayashi, Yoshimitsu, Suzuki, Mio, Kubo, Kimitoshi, Dazai, Masayoshi, Yamamoto, Junji, Oda, Hisashi, Tada, Kenji, Takahashi, Tatsuro, Miyagishima, Takuto

“…A 70-year-old male, who had undergone resection of gastric malignant lymphoma in 1992, presented with cervical lymph node swelling in January 2008…”
Get more information

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial by Denda, Tadamichi, Takashima, Atsuo, Gamoh, Makio, Iwanaga, Ichiro, Komatsu, Yoshito, Takahashi, Masanobu, Nakamura, Masato, Ohori, Hisatsugu, Sakashita, Akiko, Tsuda, Masahiro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Ishioka, Chikashi, Yamada, Yasuhide, Sato, Atsushi, Yuki, Satoshi, Morita, Satoshi, Takahashi, Shin, Yamaguchi, Tatsuro, Shimada, Ken

“…The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to…”
Get full text

Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603 by Esaki, Taito, Kawahira, Masahiro, Kusumoto, Tetsuya, Yuki, Satoshi, Hatanaka, Kazuteru, Kobayashi, Yoshimitsu, Nishie, Akihiro, Kawanami, Satoshi, Makiyama, Akitaka, Saeki, Hiroshi, Shimokawa, Mototsugu, Oki, Eiji, Maehara, Yoshihiko

“…Abstract only 509 Background: Molecular-targeted drugs are known to have angiogenesis-inhibiting properties, and thus can inhibit angiogenesis inside the tumor…”
Get full text

A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade by Motoo, Iori, Komatsu, Yoshito, Yuki, Satoshi, Nakano, Shintaro, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Muranaka, Tetsuhito, Sawada, Kentaro, Ando, Takayuki, Miyagishima, Takuto, Harada, Kazuaki, Kobayashi, Yoshimitsu, Hatanaka, Kazuteru, Ishiguro, Atsushi, Tanimoto, Aya, Honda, Takuya, Dazai, Masayoshi, Sasaki, Takahide, Sakamoto, Naoya

“…Abstract only 415 Background: It is important to predict prognosis and risk of adverse events in patients with advanced gastric cancer receiving chemotherapy…”
Get full text

Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC) by Yuki, Satoshi, Gamoh, Makio, Denda, Tadamichi, Takashima, Atsuo, Takahashi, Shin, Nakamura, Masato, Ohori, Hisatsugu, Yamaguchi, Tatsuro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Amagai, Kenji, Kondo, Hitoshi, Shimada, Ken, Sato, Atsushi, Ishioka, Chikashi, Komine, Keigo, Ouchi, Kota, Morita, Satoshi, Komatsu, Yoshito

“…Abstract only 169 Background: The TRICOLORE trial previously demonstrated that S-1+IRI+Bmab (Arm B) was non-inferior to mFOLFOX6/CapeOX+Bmab (Arm A) in terms…”
Get full text